https://old.international-biopharma.com/fda-advisers-offer-unanimous-support-to-second-bluebird-gene-therapy/ 2022-06-13T08:08:49+00:00 https://old.international-biopharma.com/dramatic-study-results-for-astrazeneca-daiichi-drug-suggest-new-way-to-treat-aggressive-breast-cancer/ 2022-06-06T07:46:04+00:00 https://old.international-biopharma.com/fda-extends-review-of-amylyx-als-drug-delaying-approval-decision/ 2022-06-06T07:42:54+00:00 https://old.international-biopharma.com/sgs/ 2022-05-26T15:47:33+00:00 https://old.international-biopharma.com/biotech-ab/ 2022-05-26T15:25:26+00:00 https://old.international-biopharma.com/chargepoint-technology/ 2022-05-26T15:13:06+00:00 https://old.international-biopharma.com/wp-content/uploads/2022/05/ChargePoint-1.jpg https://old.international-biopharma.com/wp-content/uploads/2022/05/ChargeBag-PE-S-6-743x1024-1.jpg https://old.international-biopharma.com/wp-content/uploads/2022/05/ChargePoint_Containment-2-768x513-1.png https://old.international-biopharma.com/genesis-2021-round-up-reconnecting-the-ecosystem/ 2022-05-26T14:23:17+00:00 https://old.international-biopharma.com/wp-content/uploads/2022/01/Genesis-1.png https://old.international-biopharma.com/wp-content/uploads/2022/01/Genesis-2-scaled.jpg https://old.international-biopharma.com/d-w-l/ 2022-05-26T14:17:41+00:00 https://old.international-biopharma.com/scientists-home-in-on-cause-of-duchenne-gene-therapy-side-effect/ 2022-05-25T11:57:27+00:00 https://old.international-biopharma.com/bayer-backs-out-of-atara-cell-therapy-deal/ 2022-05-25T10:47:41+00:00 https://old.international-biopharma.com/agios-to-cut-jobs-as-it-moves-away-from-exploratory-research/ 2022-05-25T10:47:14+00:00 https://old.international-biopharma.com/seagen-ceo-siegall-resigns-amid-domestic-violence-investigation/ 2022-05-25T10:46:42+00:00 https://old.international-biopharma.com/trial-setback-casts-doubt-on-a-biotechs-respiratory-virus-drug/ 2022-05-25T10:46:09+00:00 https://old.international-biopharma.com/vertex-adds-to-boston-expansion-with-plans-for-new-site/ 2022-05-25T10:45:13+00:00 https://old.international-biopharma.com/key-bristol-myers-drug-holds-up-in-long-term-psoriasis-study/ 2022-05-25T10:44:27+00:00 https://old.international-biopharma.com/roche-cancer-immunotherapy-fails-another-trial-casting-doubt-on-emerging-drug-class/ 2022-05-25T10:43:48+00:00 https://old.international-biopharma.com/modernas-finance-head-is-out-as-former-employer-conducts-investigation/ 2022-05-25T10:43:06+00:00 https://old.international-biopharma.com/pfizer-to-acquire-biohaven-in-11-6b-bet-on-biotechs-migraine-drugs/ 2022-05-25T10:42:29+00:00 https://old.international-biopharma.com/taiho-chasing-larger-rivals-buys-back-rights-to-cullinan-cancer-drug/ 2022-05-25T10:41:54+00:00 https://old.international-biopharma.com/with-spotlight-on-fda-congress-weighs-reforms-to-accelerated-drug-approvals/ 2022-05-25T10:41:02+00:00 https://old.international-biopharma.com/equipnet-enhances-their-equipment-sustainability-programs/ 2022-05-25T10:40:23+00:00 https://old.international-biopharma.com/wp-content/uploads/2022/05/equipnet-programs.jpg https://old.international-biopharma.com/biogen-ceo-to-step-down-as-company-pulls-back-from-alzheimers-drug/ 2022-05-25T10:39:43+00:00 https://old.international-biopharma.com/biogen-having-scrapped-aduhelm-tries-to-convince-investors-of-turnaround-plan/ 2022-05-25T10:39:09+00:00 https://old.international-biopharma.com/astrazeneca-and-daiichi-set-to-broaden-use-of-breast-cancer-drug-challenging-roche/ 2022-05-25T10:38:04+00:00 https://old.international-biopharma.com/fda-places-stricter-limits-on-jjs-covid-19-vaccine-after-review-of-rare-side-effect/ 2022-05-25T10:37:25+00:00 https://old.international-biopharma.com/novartis-suspends-production-of-two-radiopharmaceutical-drugs-over-quality-concerns/ 2022-05-25T10:36:25+00:00 https://old.international-biopharma.com/shimadzu-denmark-office-has-its-own-management/ 2022-05-25T10:35:43+00:00 https://old.international-biopharma.com/sonotec-with-new-flow-sensor-generation-at-interphex/ 2022-05-25T10:34:44+00:00 https://old.international-biopharma.com/wp-content/uploads/2022/05/Sonotec_sonoflow-co.55-0375-v3.0-sonotec-2_168x24px.jpg https://old.international-biopharma.com/lillys-closely-watched-diabetes-drug-scores-in-obesity-trial/ 2022-05-25T10:33:42+00:00 https://old.international-biopharma.com/recipharm-offers-services-to-enable-switch-to-next-generation-pmdi-propellants/ 2022-05-25T10:33:10+00:00 https://old.international-biopharma.com/novartis-names-longtime-analyst-as-top-dealmaker-amid-organizational-shakeup/ 2022-04-28T09:56:00+00:00 https://old.international-biopharma.com/undeterred-by-gene-therapys-struggles-a-startup-launches-into-a-downturn/ 2022-04-28T09:55:11+00:00 https://old.international-biopharma.com/fda-sets-back-novartis-best-chance-at-a-covid-19-drug/ 2022-04-28T09:51:41+00:00 https://old.international-biopharma.com/solid-bio-joins-slate-of-biotech-layoffs-shedding-35-of-its-workforce/ 2022-04-28T09:44:06+00:00 https://old.international-biopharma.com/cancer-research-uk-reveals-innovation-engine-underpinned-by-400m-portfolio-of-cutting-edge-discovery-science/ 2022-04-28T09:43:24+00:00 https://old.international-biopharma.com/jj-cuts-covid-vaccine-sales-forecasts-citing-high-supplies-and-lagging-demand/ 2022-04-28T09:42:27+00:00 https://old.international-biopharma.com/drug-price-hikes-moderate-as-rebates-rise-report-finds/ 2022-04-28T09:40:55+00:00 https://old.international-biopharma.com/a-promising-cancer-drug-leads-regeneron-to-reconsider-its-aversion-to-ma/ 2022-04-28T09:39:54+00:00 https://old.international-biopharma.com/merck-brings-former-executive-back-to-lead-ex-us-pharmaceuticals-business/ 2022-04-28T09:38:20+00:00 https://old.international-biopharma.com/seagen-to-expand-add-jobs-with-new-cancer-drug-factory/ 2022-04-28T09:36:36+00:00 https://old.international-biopharma.com/biogen-pulls-european-application-for-aduhelm-in-another-setback-for-the-alzheimers-drug/ 2022-04-28T09:35:37+00:00 https://old.international-biopharma.com/fda-panel-supports-agency-push-to-raise-approval-bar-for-certain-cancer-drugs/ 2022-04-28T09:34:21+00:00 https://old.international-biopharma.com/gsk-acquires-sierra-oncology-betting-2b-on-a-bone-cancer-drug-with-a-long-history/ 2022-04-22T11:02:43+00:00 https://old.international-biopharma.com/aacr-2022-nk-cell-promise-more-tigit-questions-and-extending-car-ts-reach/ 2022-04-22T10:57:57+00:00 https://old.international-biopharma.com/versant-backed-startup-launches-with-plans-to-broaden-cell-therapys-reach/ 2022-04-22T10:56:51+00:00 https://old.international-biopharma.com/proqr-to-lay-off-30-of-staff-following-eye-drug-setback/ 2022-04-22T10:55:52+00:00 https://old.international-biopharma.com/halozyme-doubling-down-on-a-licensing-strategy-buys-a-drug-delivery-biotech-for-nearly-1b/ 2022-04-22T10:55:19+00:00 https://old.international-biopharma.com/fda-clears-gilead-to-restart-some-studies-of-top-cancer-drug/ 2022-04-22T10:54:35+00:00 https://old.international-biopharma.com/uk-bid-to-battle-antibiotic-resistance-yields-first-subscription-style-plan/ 2022-04-22T10:53:46+00:00 https://old.international-biopharma.com/fda-advisers-grapple-with-how-to-update-covid-19-vaccines/ 2022-04-22T10:53:04+00:00 https://old.international-biopharma.com/medicare-finalizes-policy-limiting-coverage-of-biogen-alzheimers-drug/ 2022-04-22T10:51:59+00:00 https://old.international-biopharma.com/akebia-to-lay-off-42-of-workforce-suspend-trials-after-fda-drug-rejection/ 2022-04-22T10:48:37+00:00 https://old.international-biopharma.com/pfizer-buys-a-private-biotech-and-its-rsv-drug-research/ 2022-04-22T10:48:00+00:00 https://old.international-biopharma.com/regeneron-in-search-of-an-eye-gene-therapy-turns-to-a-young-biotech/ 2022-04-22T10:47:28+00:00 https://old.international-biopharma.com/novartis-breast-cancer-drug-approved-for-ultra-rare-condition/ 2022-04-22T10:46:34+00:00 https://old.international-biopharma.com/charnwood-molecular-unveils-cutting-edge-laboratories/ 2022-04-22T10:45:43+00:00 https://old.international-biopharma.com/wp-content/uploads/2022/04/Charnwood-Molecular-Photo-2-scaled.jpg https://old.international-biopharma.com/wp-content/uploads/2022/04/Charnwood-Molecular-Photo-1.jpg https://old.international-biopharma.com/wp-content/uploads/2022/04/Charnwood-Molecular-Photo-3-scaled.jpg https://old.international-biopharma.com/understanding-the-role-of-regulatory-t-cells-in-breast-cancer-metastasis/ 2022-04-04T10:33:02+00:00 https://old.international-biopharma.com/digitisation-versus-digitalisation-understanding-the-difference-and-the-role-of-lims-in-achieving-both/ 2022-04-04T10:32:34+00:00 https://old.international-biopharma.com/contamination-control-strategy/ 2022-04-04T10:32:00+00:00 https://old.international-biopharma.com/bringing-novel-therapies-to-market-5-strategies-for-success/ 2022-04-04T10:31:25+00:00 https://old.international-biopharma.com/maximising-mabs-purification-efficiency-focus-areas-for-reducing-bottlenecks-in-downstream-processing-2/ 2022-04-04T10:30:34+00:00 https://old.international-biopharma.com/cgt-cdmo-partnering-more-than-just-manufacturing/ 2022-04-04T10:28:52+00:00 https://old.international-biopharma.com/could-standardised-metadata-be-the-key-to-optimising-and-expediting-clinical-trials/ 2022-04-04T10:28:16+00:00 https://old.international-biopharma.com/benefits-key-considerations-of-using-human-ipsc-derived-disease-models-in-drug-discovery/ 2022-04-04T10:27:44+00:00 https://old.international-biopharma.com/an-end-to-end-solution-to-accelerate-car-t-cell-development-from-concept-to-clinic/ 2022-04-04T10:27:10+00:00 https://old.international-biopharma.com/slim-a-gateway-to-the-adoption-of-high-resolution-ion-mobility-for-biotherapeutic-peptide-mapping/ 2022-04-04T10:26:23+00:00 https://old.international-biopharma.com/predicting-drug-bioavailability-with-the-modern-day-toolkit/ 2022-04-04T10:24:59+00:00 https://old.international-biopharma.com/5-drugs-facing-key-patent-expirations-and-potential-generic-entry-from-december-2021-february-2022/ 2022-04-04T10:24:24+00:00 https://old.international-biopharma.com/how-involved-should-biopharma-ceos-be-in-outsourcing-activities/ 2022-04-04T10:23:53+00:00 https://old.international-biopharma.com/vertex-gets-positive-trial-results-for-non-opioid-painkiller-in-boost-to-pipeline/ 2022-04-01T09:12:58+00:00 https://old.international-biopharma.com/fda-rejects-akebia-drug-dealing-another-blow-to-anemia-pills/ 2022-04-01T09:11:43+00:00 https://old.international-biopharma.com/orchard-turns-to-layoffs-in-cutting-gene-therapy-research/ 2022-04-01T09:06:25+00:00 https://old.international-biopharma.com/fda-advisers-narrowly-side-against-an-experimental-als-drug-likely-lowering-its-approval-chances/ 2022-04-01T09:03:41+00:00 https://old.international-biopharma.com/how-a-long-shot-als-drug-came-before-the-fda/ 2022-04-01T09:02:13+00:00 https://old.international-biopharma.com/roches-top-immunotherapy-prospect-fails-study-in-tough-to-treat-lung-cancer/ 2022-04-01T09:00:22+00:00 https://old.international-biopharma.com/adagio-plans-comeback-for-covid-drug-but-is-it-too-late/ 2022-04-01T08:58:15+00:00 https://old.international-biopharma.com/novartis-turns-cell-therapy-skill-into-contract-manufacturing-deal/ 2022-03-31T09:27:52+00:00 https://old.international-biopharma.com/bluebirds-cfo-resigns-as-cash-woes-raise-doubts-about-its-future/ 2022-03-31T09:24:40+00:00 https://old.international-biopharma.com/we-have-to-make-a-stand-biotech-leaders-vow-to-break-ties-with-russia-over-ukraine-war-2/ 2022-03-31T09:15:18+00:00 https://old.international-biopharma.com/fda-panel-to-review-once-rejected-acadia-drug-for-psychosis/ 2022-03-31T09:13:23+00:00 https://old.international-biopharma.com/sanofi-with-positive-data-in-hand-to-ask-for-approval-of-longer-lasting-hemophilia-therapy/ 2022-03-31T09:08:38+00:00 https://old.international-biopharma.com/how-mercks-puzzling-results-could-impact-immunotherapys-role-in-early-lung-cancer/ 2022-03-31T09:07:54+00:00 https://old.international-biopharma.com/moderna-citing-need-for-flexibility-seeks-broad-clearance-of-fourth-covid-shot/ 2022-03-31T09:07:14+00:00 https://old.international-biopharma.com/alnylam-sues-pfizer-moderna-over-technology-used-in-covid-vaccines/ 2022-03-31T09:06:25+00:00 https://old.international-biopharma.com/with-trial-success-in-kidney-disease-lilly-boehringer-make-case-for-broader-use-of-diabetes-drug/ 2022-03-31T09:05:20+00:00 https://old.international-biopharma.com/nektar-bristol-myers-drug-combination-fails-in-late-stage-melanoma-trial/ 2022-03-31T09:04:48+00:00 https://old.international-biopharma.com/how-to-eliminate-design-verification-failure-for-your-next-device/ 2022-03-31T09:04:09+00:00 https://old.international-biopharma.com/fda-as-expected-rejects-lilly-and-innovent-immunotherapy-in-signal-to-drugmakers/ 2022-03-31T09:02:40+00:00 https://old.international-biopharma.com/gsk-partners-with-lifemine-as-startups-advance-plans-to-make-drugs-from-fungi/ 2022-03-31T09:01:48+00:00 https://old.international-biopharma.com/novartis-wins-fda-ok-for-radiopharmaceutical-drug-cashing-in-on-endocyte-deal/ 2022-03-31T09:00:57+00:00 https://old.international-biopharma.com/as-biotech-retreats-gene-therapy-companies-retrench-and-redraw-plans/ 2022-03-31T08:59:57+00:00 https://old.international-biopharma.com/moderna-with-new-data-to-seek-clearance-for-covid-19-vaccine-in-young-children/ 2022-03-31T08:59:15+00:00 https://old.international-biopharma.com/pfizer-claims-study-success-for-drug-key-to-arena-buyout/ 2022-03-31T08:58:34+00:00 https://old.international-biopharma.com/vertex-plans-path-to-fda-for-top-drug-prospect/ 2022-03-31T08:56:18+00:00 https://old.international-biopharma.com/after-slower-than-expected-review-pfizer-and-arena-close-buyout-deal/ 2022-03-31T08:55:38+00:00 https://old.international-biopharma.com/abbvie-keeps-up-dealmaking-pace-in-neuroscience/ 2022-03-31T08:48:27+00:00 https://old.international-biopharma.com/biden-discusses-drug-prices-mental-health-services-in-annual-address/ 2022-03-31T08:45:16+00:00 https://old.international-biopharma.com/civica-targets-insulin-in-effort-to-produce-cheaper-drugs/ 2022-03-31T08:43:25+00:00 https://old.international-biopharma.com/biogen-struggling-to-sell-alzheimers-drug-begins-layoffs-to-save-money/ 2022-03-31T08:42:21+00:00 https://old.international-biopharma.com/we-have-to-make-a-stand-biotech-leaders-vow-to-break-ties-with-russia-over-ukraine-war/ 2022-03-31T08:41:07+00:00 https://old.international-biopharma.com/amid-biotech-downturn-atlas-raises-450m-to-build-new-drug-startups/ 2022-03-31T08:40:19+00:00 https://old.international-biopharma.com/roche-nearing-major-trial-readouts-starts-new-alzheimers-drug-study/ 2022-03-31T08:39:25+00:00 https://old.international-biopharma.com/fda-sets-back-karyopharms-bid-to-broaden-use-of-cancer-drug/ 2022-03-31T08:38:28+00:00 https://old.international-biopharma.com/sanofi-and-gsk-after-delays-to-seek-clearance-for-covid-19-vaccine/ 2022-03-04T12:55:54+00:00 https://old.international-biopharma.com/astrazeneca-daiichi-press-rivals-with-new-results-for-breast-cancer-drug/ 2022-03-04T12:54:54+00:00 https://old.international-biopharma.com/lilly-puts-700m-into-genetic-medicine-institute/ 2022-03-04T12:54:09+00:00 https://old.international-biopharma.com/kodiak-crashes-on-negative-trial-results-for-would-be-eylea-competitor/ 2022-03-04T12:52:55+00:00 https://old.international-biopharma.com/adagio-pledges-to-press-forward-with-covid-drug-as-ceo-to-resign/ 2022-03-04T12:52:06+00:00 https://old.international-biopharma.com/moderna-on-the-heels-of-pharma-rivals-cleared-to-advance-rsv-vaccine/ 2022-03-04T12:51:03+00:00 https://old.international-biopharma.com/spark-ceo-marrazzo-who-led-company-to-historic-gene-therapy-approval-to-step-down/ 2022-03-04T12:50:14+00:00 https://old.international-biopharma.com/yumanity-cutting-60-of-employees-as-it-mulls-possible-sale/ 2022-03-04T12:49:28+00:00 https://old.international-biopharma.com/sage-claims-new-data-show-depression-drug-works-but-doubts-remain/ 2022-03-04T12:43:52+00:00 https://old.international-biopharma.com/star-therapeutics-emerges-with-plans-to-treat-rare-diseases-through-a-solar-system-of-drug-companies/ 2022-03-04T12:43:06+00:00 https://old.international-biopharma.com/califf-confirmed-as-fda-chief-in-close-vote-ending-protracted-vacancy-at-health-agency/ 2022-03-04T12:42:07+00:00 https://old.international-biopharma.com/bristol-myers-gets-fda-decision-date-for-earlier-use-of-car-t-therapy/ 2022-03-04T12:41:09+00:00 https://old.international-biopharma.com/jj-to-explore-rna-reprogramming-with-remix-research-deal/ 2022-03-04T12:40:17+00:00 https://old.international-biopharma.com/third-harmonic-led-by-former-audentes-ceo-launches-with-155m-in-funding/ 2022-03-04T12:39:22+00:00 https://old.international-biopharma.com/al-sandrock-former-top-biogen-scientist-to-join-drug-discovery-startups-board/ 2022-03-04T12:38:13+00:00 https://old.international-biopharma.com/why-the-fda-is-making-a-test-case-of-a-cancer-drug-from-china/ 2022-03-04T12:37:25+00:00 https://old.international-biopharma.com/the-pipeline-of-new-antibiotics-is-drying-up-a-bill-in-congress-aims-to-change-that-2/ 2022-03-04T12:33:36+00:00 https://old.international-biopharma.com/pressure-rises-as-gilead-awaits-important-study-results-for-top-cancer-drug-2/ 2022-03-04T12:32:43+00:00 https://old.international-biopharma.com/pressed-by-wall-street-pharma-executives-signal-openness-to-ma/ 2022-03-04T12:31:00+00:00 https://old.international-biopharma.com/editas-executive-shake-up-continues/ 2022-03-04T12:09:59+00:00 https://old.international-biopharma.com/pfizer-forecasts-100b-in-sales-fueled-by-covid-19-vaccine-pill/ 2022-03-04T12:08:39+00:00 https://old.international-biopharma.com/intellia-expanding-in-gene-editing-buys-startup-rewrite-for-45m/ 2022-03-04T12:08:03+00:00 https://old.international-biopharma.com/in-england-orchard-secures-rare-agreement-on-gene-therapy-coverage/ 2022-03-04T12:07:11+00:00 https://old.international-biopharma.com/the-pipeline-of-new-antibiotics-is-drying-up-a-bill-in-congress-aims-to-change-that/ 2022-03-04T12:05:44+00:00 https://old.international-biopharma.com/pfizer-lures-research-chief-from-roche-prompting-high-level-reshuffle/ 2022-03-04T12:03:34+00:00 https://old.international-biopharma.com/pressure-rises-as-gilead-awaits-important-study-results-for-top-cancer-drug/ 2022-03-04T12:02:31+00:00 https://old.international-biopharma.com/biogens-alzheimers-drug-sales-remain-slow-as-company-warns-of-further-cost-cuts/ 2022-03-04T11:53:21+00:00 https://old.international-biopharma.com/lilly-slows-fda-submission-of-alzheimers-drug-after-medicare-decision/ 2022-03-04T11:52:23+00:00 https://old.international-biopharma.com/tive/ 2022-02-24T14:28:51+00:00 https://old.international-biopharma.com/celonic/ 2022-02-02T14:18:14+00:00 https://old.international-biopharma.com/qualogy-regulatory-archive/ 2022-01-31T15:13:52+00:00 https://old.international-biopharma.com/a-biotech-wins-the-first-fda-drug-approval-in-a-rare-type-of-eye-cancer/ 2022-01-27T11:06:16+00:00 https://old.international-biopharma.com/incyte-withdraws-cancer-drug-from-fda-review-after-discussions-with-regulator/ 2022-01-27T11:02:36+00:00 https://old.international-biopharma.com/with-new-trial-pfizer-and-biontech-will-test-whether-an-omicron-vaccine-is-needed/ 2022-01-27T11:00:32+00:00 https://old.international-biopharma.com/merck-drug-for-chronic-cough-rejected-by-fda/ 2022-01-27T10:58:58+00:00 https://old.international-biopharma.com/moderna-follows-pfizer-in-beginning-trial-of-omicron-vaccine/ 2022-01-27T10:57:05+00:00 https://old.international-biopharma.com/cortexyme-to-shift-focus-after-fda-places-hold-on-experimental-alzheimers-drug/ 2022-01-27T10:52:09+00:00 https://old.international-biopharma.com/gene-editing-startup-metagenomi-raises-175m-to-advance-research-pipeline/ 2022-01-27T10:48:43+00:00 https://old.international-biopharma.com/eqrx-builds-case-for-cancer-drug-it-hopes-can-disrupt-market/ 2022-01-20T15:45:28+00:00 https://old.international-biopharma.com/fda-approves-abbvie-pfizer-drugs-for-eczema-creating-competition-for-sanofi/ 2022-01-20T15:43:39+00:00 https://old.international-biopharma.com/gsk-loses-rd-chief-barron-to-high-powered-startup-amid-investor-pressure/ 2022-01-20T15:40:45+00:00 https://old.international-biopharma.com/roche-revives-a-closely-watched-huntingtons-disease-drug/ 2022-01-20T15:38:43+00:00 https://old.international-biopharma.com/bluebird-faces-longer-wait-for-fda-verdict-on-experimental-gene-therapies/ 2022-01-20T15:36:17+00:00 https://old.international-biopharma.com/ucb-to-buy-zogenix-for-nearly-2b-in-first-step-for-ma-in-2022/ 2022-01-20T15:33:53+00:00 https://old.international-biopharma.com/amgen-partners-with-arrakis-to-develop-drugs-aimed-at-rna/ 2022-01-14T10:19:25+00:00 https://old.international-biopharma.com/medicare-proposes-to-limit-coverage-of-biogen-alzheimers-drug/ 2022-01-14T10:17:48+00:00 https://old.international-biopharma.com/aftershocks-for-lilly-crispr-versus-crispr-and-bluebirds-crucial-year/ 2022-01-14T10:13:15+00:00 https://old.international-biopharma.com/pfizers-big-bet-on-mrna-biogen-proven-wrong-on-aduhelm-price-and-the-next-cell-therapies/ 2022-01-14T10:10:12+00:00 https://old.international-biopharma.com/ma-anxiety-roches-comeback-plan-and-virs-omicron-moment/ 2022-01-14T10:08:09+00:00 https://old.international-biopharma.com/sarepta-with-new-duchenne-results-to-broach-possibility-of-speedy-gene-therapy-approval/ 2022-01-14T10:06:23+00:00 https://old.international-biopharma.com/allogene-cleared-by-fda-to-resume-off-the-shelf-cancer-cell-therapy-trials/ 2022-01-14T10:04:25+00:00 https://old.international-biopharma.com/fujifilm-wako-chemicals-u-s-a-corporation/ 2022-01-11T15:28:29+00:00 https://old.international-biopharma.com/wp-content/uploads/2022/01/Fuji-1.jpg https://old.international-biopharma.com/wp-content/uploads/2022/01/Fuji-2.jpg https://old.international-biopharma.com/novartis-wins-fda-approval-for-new-heart-drug-but-faces-uphill-sales-battle/ 2022-01-07T16:12:42+00:00 https://old.international-biopharma.com/novartis-ups-investment-in-gene-therapy-for-the-eye-with-800m-buyout/ 2022-01-07T16:09:52+00:00 https://old.international-biopharma.com/allakos-shares-plunge-as-companys-top-drug-falls-short-in-studies/ 2022-01-07T16:08:07+00:00 https://old.international-biopharma.com/gilead-following-merck-hits-its-own-safety-setback-in-hiv/ 2022-01-07T16:05:55+00:00 https://old.international-biopharma.com/covid-19-pills-from-pfizer-merck-authorized-by-fda-in-major-pandemic-milestone/ 2022-01-07T16:01:42+00:00 https://old.international-biopharma.com/after-years-of-decline-drugmakers-price-hikes-may-have-bottomed-out/ 2022-01-07T15:38:49+00:00 https://old.international-biopharma.com/lilly-pours-more-money-into-genetic-treatments-for-neurological-diseases/ 2022-01-07T15:33:16+00:00 https://old.international-biopharma.com/adagio-after-bold-promises-says-antibody-drug-wont-work-well-against-omicron/ 2021-12-16T13:46:46+00:00 https://old.international-biopharma.com/biogen-reserves-four-years-for-trial-meant-to-confirm-its-alzheimers-drug-works/ 2021-12-16T13:43:43+00:00 https://old.international-biopharma.com/sanofi-gsk-say-covid-vaccine-works-as-booster-but-delay-key-study-results/ 2021-12-16T13:40:42+00:00 https://old.international-biopharma.com/two-cancer-cell-therapy-studies-succeeded-why-did-a-third-fail/ 2021-12-15T14:56:27+00:00 https://old.international-biopharma.com/bristol-myers-returns-to-immatics-for-a-dual-targeting-cancer-drug/ 2021-12-15T14:52:57+00:00 https://old.international-biopharma.com/in-final-analysis-pfizers-covid-19-pill-remains-highly-effective/ 2021-12-15T14:29:31+00:00 https://old.international-biopharma.com/rebounding-from-setbacks-sanofi-reveals-promising-data-for-hemophilia-drug/ 2021-12-15T14:27:17+00:00 https://old.international-biopharma.com/a-high-profile-gene-therapy-biotech-takes-aim-at-huntingtons/ 2021-12-15T14:04:56+00:00 https://old.international-biopharma.com/gsk-sets-sights-on-brain-diseases-through-oxford-partnership/ 2021-12-13T14:22:07+00:00 https://old.international-biopharma.com/former-immunomedics-executive-charged-with-insider-trading-around-trial-data/ 2021-12-13T14:13:18+00:00 https://old.international-biopharma.com/lilly-deepens-research-ties-in-china-with-biotech-deal/ 2021-12-13T13:49:54+00:00 https://old.international-biopharma.com/moderna-reveals-first-study-results-for-seasonal-flu-vaccine/ 2021-12-13T13:42:47+00:00 https://old.international-biopharma.com/latest-roche-results-show-promise-for-new-type-of-cancer-immunotherapy/ 2021-12-13T13:39:10+00:00 https://old.international-biopharma.com/arena-completing-its-turnaround-sells-to-pfizer-for-nearly-7-billion/ 2021-12-13T13:34:15+00:00 https://old.international-biopharma.com/biohaven-to-seek-fda-approval-for-second-migraine-drug-after-study-success/ 2021-12-10T14:01:29+00:00 https://old.international-biopharma.com/abbvies-blockbuster-weighed-down-by-safety-concerns-for-a-similar-pfizer-drug/ 2021-12-10T13:43:56+00:00 https://old.international-biopharma.com/acadia-shares-rise-on-study-success-for-rett-syndrome-drug/ 2021-12-10T13:41:19+00:00 https://old.international-biopharma.com/martin-shkrelis-former-company-to-pay-40m-in-settlement-over-drug-price-hikes/ 2021-12-10T13:39:14+00:00 https://old.international-biopharma.com/lilly-drug-becomes-first-covid-antibody-cleared-for-use-in-young-children/ 2021-12-10T13:28:53+00:00 https://old.international-biopharma.com/intercept-awaiting-needed-trial-data-pulls-its-nash-drug-application-in-europe/ 2021-12-10T12:00:37+00:00 https://old.international-biopharma.com/astrazeneca-wagers-200m-on-ionis-next-chance-at-a-rare-disease-drug/ 2021-12-10T11:58:15+00:00 https://old.international-biopharma.com/a-serial-biotech-entrepreneur-launches-his-next-startup-with-high-dollar-backing/ 2021-12-10T11:35:14+00:00 https://old.international-biopharma.com/vaccine-from-medicago-gsk-protective-against-covid-19-in-large-study/ 2021-12-10T11:32:13+00:00 https://old.international-biopharma.com/astrazeneca-antibody-cleared-by-fda-for-preventive-use-against-covid-19/ 2021-12-10T11:27:54+00:00 https://old.international-biopharma.com/optibrium-shows-deep-learning-to-successfully-predict-human-panel-based-sensory-perception-of-novel-compounds-used-for-flavours-and-fragrances/ 2021-12-10T11:24:42+00:00 https://old.international-biopharma.com/fda-panel-turns-down-reata-kidney-disease-drug-in-unanimous-vote/ 2021-12-10T11:21:33+00:00 https://old.international-biopharma.com/fresh-data-show-uniqures-hemophilia-gene-therapy-appears-to-hold-up/ 2021-12-10T11:15:47+00:00 https://old.international-biopharma.com/omicron-cuts-pfizer-vaccines-potency-but-data-show-booster-may-restore-protection/ 2021-12-10T11:09:35+00:00 https://old.international-biopharma.com/accelerating-single-cell-genomic-sequencing-with-big-memory/ 2021-12-09T15:20:02+00:00 https://old.international-biopharma.com/innovations-in-cell-line-development-to-optimise-biotherapeutic-development/ 2021-12-09T15:19:25+00:00 https://old.international-biopharma.com/residual-impurities-in-biopharmaceutical-products/ 2021-12-09T15:18:42+00:00 https://old.international-biopharma.com/el-standards-empowering-confident-labware-choices/ 2021-12-09T15:18:17+00:00 https://old.international-biopharma.com/viral-vector-engineering-to-improve-clinical-performance-and-accelerate-timeline-to-success-for-novel-gene-therapies/ 2021-12-09T15:17:50+00:00 https://old.international-biopharma.com/are-we-nearly-there-yet-the-ongoing-journey-of-car-t-cell-therapies/ 2021-12-09T15:17:20+00:00 https://old.international-biopharma.com/crispr-cas9-knockout-screening-using-primary-human-cells-in-drug-discovery/ 2021-12-09T15:16:55+00:00 https://old.international-biopharma.com/how-to-bring-your-oncolytic-virus-innovation-to-market-the-secret-to-successful-development/ 2021-12-09T15:16:28+00:00 https://old.international-biopharma.com/regulatory-challenges-associated-with-the-development-of-cell-and-gene-therapies/ 2021-12-09T15:15:55+00:00 https://old.international-biopharma.com/divided-by-a-common-language-pv-differences-between-the-uk-and-the-us-notes-for-ambitious-biotechs/ 2021-12-09T15:15:27+00:00